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ABSTRACT
The seroprevalence of Toxoplasma gondii in the northern Greek population was determined in 1984, 1994
and 2004, and changes during this period were investigated. In total, 1014, 812 and 958 sera from
individuals aged 1 day to 70 years were examined in 1984, 1994 and 2004, respectively, for IgG and IgM
anti-Toxoplasma antibodies with the standard immunofluorescence assay (IFA) and microparticle enzyme
immunoassay (MEIA). In individuals positive for IgM-specific antibodies, primary infection with
Toxoplasmawas diagnosed on the basis of the Toxoplasma serological profile (IFA,MEIA, conventional IgM
and IgA ELISAs, immunosorbent agglutination assay and IgG avidity test). The prevalence of IgG-specific
antibodies in the general population was 37%, 29.9% and 24.1% in 1984, 1994 and 2004, respectively, and
was 35.6%, 25.6% and 20%, respectively, in women of reproductive age (15–39 years). The incidence of
Toxoplasma infection, basedon cases of primary infection and the annual seroconversion rate for thegeneral
population, was estimated to be 1.25% and 1.1% in 1984, 1.05% and 0.93% in 1994, and 0.85% and 0.8% in
2004. The significant decline in prevalence, and the shift towards an older age group, observed during this
period couldbe explainedby the improvedsocio-economic situation.Thehigh (80%) proportionofwomen
of reproductive age susceptible toToxoplasma infection,with an estimated 90–200 neonates infected in utero
annually, seems to present a potential risk to public health. Education of the public and prophylactic
measures may become increasingly important.
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INTRODUCTION
Toxoplasmosis is a zoonotic disease caused by
Toxoplasma gondii. Although the course of infec-
tion is generally benign, this organism can cause
significant morbidity and mortality in the devel-
oping foetus and in immunocompromised indi-
viduals [1]. As an effective vaccine has not yet
been developed, continuous and detailed epide-
miological surveillance is required to estimate the
risk of infection, especially in pregnant women,
and the likelihood of reactivation in immunocom-
promised individuals.
The first seroepidemiological study of T. gondii
in the regions of Macedonia and Thrace (northern
Greece) was conducted in 1972, and revealed a
prevalence rate of 43% [2]. The present study,
performed in 2004, determined the prevalence
and incidence of Toxoplasma infection in individ-
uals aged 1 day to 70 years from the same area, as
well as in the sub-population comprising women
of reproductive age. The results obtained were
compared with those from similar surveys per-
formed in 1984 and 1994 [3,4].
MATERIALS AND METHODS
Study population
The individuals examined in 1984, 1994 and 2004 were
selected randomly from the general population living in
rural and urban areas of the 16 prefectures in northern
Greece (population 2.8 million) [5]. The number of individ-
uals tested from each prefecture was proportional to the
population of the respective region. Serum samples were
obtained from apparently healthy individuals, as follows:
children who were participating in screening programmes
for prevention of haemoglobulinopathies and for investiga-
tion of lipidaemic profiles; women tested before and during
pregnancy; and adults who attended the hospital for an
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annual medical check-up or for blood donation. In total,
1014 sera were tested in 1984 (470 males, 544 females), 812
in 1994 (390 males, 422 females), and 958 in 2004 (460 males,
498 females). All participants were grouped into ten age
groups: 0–0.9, 1–4, 5–9, 10–14, 15–19, 20–29, 30–39, 40–49,
50–59 and 60–70 years. Women of reproductive age
(15–39 years) were also studied as a separate group. The
sera were stored at ) 70C until required for analysis.
Serological methods
All serum samples were examined for the presence of
Toxoplasma-specific IgG and IgM antibodies separately. IgG
antibodies were measured using an in-house immunofluores-
cence assay (IFA) [6], with results expressed in IU ⁄mL, based
on the WHO first standard serum 1967 [7]. Values ‡ 12 IU ⁄mL
were considered to be positive. In the case of equivocal results,
the respective sera were also tested for specific IgG antibodies
by microparticle enzyme immunoassay (IgG-MEIA; Abbott
Laboratories, Chicago, IL, USA). IgM-specific antibodies were
detected using IgM-MEIA (Abbott Laboratories).
IgM-positive sera were further tested by: (1) other IgM
detection methods, including an in-house IFA assay (IgM-IFA;
positive = ‡ 1:50 dilution), an immunosorbent agglutination
assay (bioMe´rieux, Marcy l’Etoile, France), and a Western
blotting test for specific IgM antibodies against the 30-kDa
peptide (MarDx Diagnostics, Carlsbad, CA, USA); (2) a
sensitive capture ELISA detecting IgA-specific antibodies
(Bouty SpA, Sesto S. Giovanni, Italy; positive = ‡ 10 AU ⁄mL);
and (3) an assay measuring the avidity of IgG-specific
antibodies (Bouty SpA), where an avidity of < 15% indicates
an acute primary infection during the last 2–3 months, 15–25%
indicates a primary infection during the last 6 months, and
> 25% indicates an older infection.
Sera were tested by both IgG-IFA and IgM-IFA, or only by
IgM-MEIA, at the time of collection. The additional methods
for IgM, IgA and for determining the avidity of IgG antibodies
were performed in 2004 for all IgM-positive sera.
Diagnostic criteria for Toxoplasma primary infection
A positive IgM result has a low predictive value for identifying
a primary infection with Toxoplasma [8,9]. A combination of
serological assays can be used to determine the onset of
infection with more certainty [10]. In the present study, a
primary infection was considered to have occurred recently
(i.e., during the previous 5–6 months) if there was a combina-
tion of high titres of IgG-IFA, positive IgM antibodies, and a
low-avidity IgG antibody index (< 25%) in a single serum
sample [8–12]. The incidence of primary infection with
Toxoplasma was estimated from (1) the number of cases of
primary infection ⁄ year, and (2) the annual seroconversion rate
of the age-specific seroprevalence [13].
Statistical methods
The chi-square test was used to compare differences in
prevalence rates between age groups and to assess trends
over time. A p value of < 0.05 was considered to be significant.
Biostatistical analysis was performed using SPSS for Windows
v. 10.0.1 (SPSS Inc., Chicago, IL, USA).
RESULTS
Immune status against T. gondii
A summary of all serological tests used and the
diagnosis of immune status, based on the com-
bined results, is shown in Table 1. The frequency
of IgG-IFA anti-Toxoplasma antibodies in 1984,
1994 and 2004 is shown in Table 2. In all three
years, seropositivity rose gradually with age; this
rise was most rapid in 1984 and became slower in
1994 and in 2004. Thus, only a small proportion of
children aged 1–4 and 5–9 years (3.2% and 7.4%,
respectively) were positive in 2004, and the
seroprevalence then rose gradually until the age
of 49 years (33.3%). A significantly higher rate
(50%) was found only in the group aged
50–59 years (p 0.019), with the highest rate
(56.4%) in the group aged 60–70 years. No signi-
ficant difference was found between men and
women, except in 2004 for the group aged
Table 1. Determination of immune status for Toxoplasma gondii in the general population of northern Greece (1984, 1994
and 2004)
Year
IgG-IFA
IgM-IFA-
positive
IgM-MEIA-
positive
IgM-ISAGA-
positive
IgM-WB-
positive
IgA-ELISA-
positive
IgG avidity
Immune status
Result
(IU/mL)
No.
positive sera Result
No.
sera
1984:
1014 sera tested
12–800 374 9 9 9 2 3 > 25% 9 Old infection
400–3200 4 2 4 4 4 3 < 25% 4 Recent infectiona
< 12 634 0 ND ND ND ND Negative
< 12 2 2 1 0 0 0 Negative
1994:
812 sera tested
12–400 239 10 14 13 6 5 > 25% 14 Old infection
400–1600 3 2 3 3 3 3 < 25% 3 Recent infectiona
< 12 567 ND 0 ND ND ND Negative
< 12 3 1 3 1 0 0 Negative
2004:
958 sera tested
12–800 228 6 9 7 5 2 > 25% 9 Old infection
200–1600 3 3 3 3 3 3 < 25% 3 Recent infectiona
< 12 723 ND 0 ND ND ND Negative
< 12 4 2 4 2 0 0 Negative
aPrimary infection acquired during the previous 6 months.
IFA, immunofluorescence assay; MEIA, microparticle enzyme immunoassay; ISAGA, immunosorbent agglutination assay; WB, Western blot; ND, not determined.
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60–70 years (43% in men vs. 56.4% in women;
p 0.003). Overall, the seroprevalence rate in the
general population in 2004 was 24.1%, which was
significantly lower than the rates of 29.9% in 1994
(p 0.001) and 37% in 1984 (p 0.0059).
Incidence of primary infection with Toxoplasma
in the general population
The two approaches used to calculate the inci-
dence of primary Toxoplasma infection provided
similar results (Table 3). Thus: (1) a primary
infection was identified during the previous
6 months for four cases in 1984, three cases in
1994 and three cases in 2004, with estimated
incidences of primary infection of 1.25, 1.05 and
0.83 ⁄ 100 seronegative individuals ⁄year in 1984,
1994 and 2004, respectively; (2) the age-specific
incidence of primary infection, estimated from the
annual rate of seroconversion, increased annually
by c. 1.1% in 1984, 0.93% in 1994 and 0.8% in
2004.
Prevalence and incidence of Toxoplasma
infection in women of reproductive age
The prevalence of Toxoplasma infection in women
of reproductive age (15–39 years) was 35.6% in
1984, 25.6% in 1994 and 20% in 2004 (Table 3).
Based on the number of cases of primary infec-
tion, the incidence ⁄pregnancy was estimated to
be 0.69% in 1984, 0.67% in 1994 and 0.55% in
2004, while the annual seroconversion rate was
0.81% in 1984, 0.55% in 1994 and 0.48% in 2004.
The mean incidence of primary infection ⁄preg-
nancy was 0.51% in 2004.
DISCUSSION
The present study showed that 24.1% of healthy
individuals in northern Greece, aged 1 day to
70 years, were positive for anti-Toxoplasma anti-
bodies in 2004, and that 20% of women of
reproductive age in the same population were
seropositive. These seropositivity rates are signi-
ficantly lower than rates reported in central
European countries, but higher than those in the
UK and in Scandinavian countries. Prevalence
rates in the overall population have been reported
to be > 50% in France [14], 52.4% in Switzerland
[15], and 59% in Germany [16], while rates in
women of reproductive age have been reported to
be 20.3% in Finland [17], 10.9% in Norway [9],
8.1% in England [18], 40% in Switzerland [15],
and 54.3% in France [19]. Differences in the
prevalence of Toxoplasma infection have been
associated with warm and humid environments,
cooking habits and the number of cats living
outdoors, but the exact roles of these factors are
still not fully understood [20,21]. In northern
Greece, the climate is warm and humid during
the summer, but is cold during winter, and raw or
undercooked meat is eaten very rarely.
In 1966, Fulton et al. [22] found a high serop-
ositivity rate of 60% in southern Greece with the
Dye test, and a rate of 43% was found in northern
Greece in 1972 with the same test [2]. A significant
decline in the prevalence of Toxoplasma infection
was observed in northern Greece in 1984 and 1994
(37.3% and 29.8%, respectively), dropping to
24.1% in 2004 in the present study. Various
studies from Europe [23] and the USA [20] have
also reported a decrease in the seroprevalence of
Toxoplasma infection during the past 20–30 years.
The reason for this is not clear, although it may
Table 2. Age-specific seroprevalence against Toxoplasma
gondii in the northern Greek population
Age
(years)
1984 1994 2004
r ⁄ n % r ⁄ n % r ⁄ n %
0–0.9 21 ⁄ 131 16 11 ⁄ 73 15.1a 10 ⁄ 87 11.5a
1–4 11 ⁄ 94 11.7 3 ⁄ 67 4.5 3 ⁄ 93 3.2
5–9 18 ⁄ 101 17.8 8 ⁄ 98 8.2 7 ⁄ 94 7.4
10–14 14 ⁄ 59 23.7 3 ⁄ 34 8.8 9 ⁄ 84 10.7
15–19 20 ⁄ 80 25 8 ⁄ 48 16.7 12 ⁄ 82 14.6
20–29 42 ⁄ 124 33.9a 38 ⁄ 155 24.5 22 ⁄ 104 21.2
30–39 52 ⁄ 106 49.1 30 ⁄ 99 30.3a 28 ⁄ 110 25.5
40–49 67 ⁄ 110 61 48 ⁄ 92 52.2 38 ⁄ 114 33.3a
50–59 65 ⁄ 98 66.3 42 ⁄ 68 61.8 40 ⁄ 80 50
60–70 68 ⁄ 111 61.3 51 ⁄ 78 65.4 62 ⁄ 110 56.4b
Total number 378 ⁄ 1014 37.3 242 ⁄ 812 29.8c 231 ⁄ 958 24.1d
aSignificant difference compared to next age group.
bSignificant difference between men and women.
cp 0.001 (1984–1994).
dp 00059 (1994–2004).
r, number seropositive; n, sample size.
Table 3. Seroprevalence and incidence among population
groups in northern Greece
Population
groups
Incidence (%)
Prevalence (%)
Cases of primary
infection
Annual serocon-
version rate
1984 1994 2004 1984 1994 2004 1984 1994 2004
General
population
37.3 29.8 24.1 1.25a 1.05a 0.85a 1.1a 0.93a 0.8a
Women aged
15–39 years
35.6 25.6 20 0.69b 0.67b 0.5b 0.8b 0.5b 0.4b
aIncidence ⁄ year.
bIncidence ⁄pregnancy.
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result from changes in the rate of exposure of
susceptible individuals to tissue cysts or oocyst-
contaminated environmental reservoirs. In nor-
thern Greece, this gradual decrease may be
explained by the improved socio-economic situ-
ation. Reduced consumption of home-grown fruit
and vegetables, wide consumption of pasteurised
milk, and the increasing use of freezers in the
home, may be some of the factors that have led to
a decrease in human infection, as well as
increased awareness and education with respect
to eating adequately cooked meat, keeping cats,
hygienic vegetable preparation and hand washing
[24]. No recent studies in the general population
have been reported from southern Greece.
In the present study, the prevalence rate in 2004
increased with age, from 3.2% in the group aged
1–4 years, to 56.4% in the group aged
60–69 years, with analogous increases in seropo-
sitivity in 1984 and 1994. There was a clear decline
in the prevalence in each age group from decade
to decade (Table 2). A cohort effect was observed
for the group aged 20–29 years in 1984. The
observed shift towards older age groups could
be explained by the fact that increasingly large
numbers of people in Greece live in apartments
without gardens, so that children grow up away
from gardens, soil and animals. However, other
factors may also have influenced this shift, as
different sources of infection are found in differ-
ent age groups [25].
As with seroprevalence, the incidence of pri-
mary infection with Toxoplasma in the general
population, as well as in women of reproductive
age, seems to have decreased during the last
20 years in northern Greece. In the group of
women of reproductive age, the incidence, as
estimated by the cases of primary infection,
decreased from 0.69% ⁄pregnancy in 1984 to
0.55% in 2004, while the incidence estimated by
the annual seroconversion rate was found to have
declined from 0.81% ⁄pregnancy in 1984 to 0.48%
in 2004. Similar decreases have been reported
from some other countries [23,26], with values
ranging between 0.06% and 1.48% during preg-
nancy [19,20,27].
The prevalence of T. gondii infection showed a
significant decreasing trend in northern Greece
during the study period, resulting in a high (80%)
proportion of non-immune women of reproduc-
tive age. Based on an estimated incidence in 2004
of 0.51% ⁄pregnancy, an assumed maternofetal
transmission rate of 23–50% [9,20,27], and an
annual birth rate of 100 000 in Greece, it can be
calculated that c. 408 pregnant women are infec-
ted annually with Toxoplasma during their preg-
nancy, and that 90–200 children are infected
in utero by T. gondii. The present results are not
representative of the entire country, so further
studies should be performed to establish the
complete picture of Toxoplasma infection in
Greece. In parallel, it is also important to inform
and educate the public on how to avoid possible
risk-factors and prevent Toxoplasma infection.
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